Truist Financial Corp Halozyme Therapeutics, Inc. Transaction History

Truist Financial Corp

$62.9 Billion
Q3 2024

A detailed history of Truist Financial Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Truist Financial Corp holds 75,234 shares of HALO stock, worth $3.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

75,234

Previous 84,465 10.93%

Holding current value

$3.59 Million

Previous $4.42 Million 2.67%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$51.3 - $64.42 $473,550 - $594,661	-9,231 Reduced 10.93%	75,234 $4.3 Million
Q2 2024 Aug 20, 2024	SELL	$37.81 - $52.4 $638,081 - $884,302	-16,876 Reduced 16.65%	84,465 $4.42 Million
Q1 2024 May 10, 2024	SELL	$33.68 - $41.95 $43,144 - $53,737	-1,281 Reduced 1.25%	101,341 $4.12 Million
Q4 2023 Feb 02, 2024	BUY	$33.32 - $42.1 $18,759 - $23,702	563 Added 0.55%	102,622 $3.79 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $56,622 - $68,378	1,553 Added 1.55%	102,059 $3.9 Million
Q2 2023 Aug 01, 2023	BUY	$30.28 - $38.74 $98,833 - $126,447	3,264 Added 3.36%	100,506 $3.63 Million
Q1 2023 May 05, 2023	BUY	$32.86 - $55.7 $371,186 - $629,187	11,296 Added 13.14%	97,242 $3.71 Million
Q4 2022 Feb 17, 2023	BUY	$40.06 - $59.44 $482,122 - $715,360	12,035 Added 16.28%	85,946 $4.89 Million
Q3 2022 Oct 26, 2022	BUY	$38.53 - $51.78 $1.68 Million - $2.26 Million	43,581 Added 143.69%	73,911 $2.92 Million
Q2 2022 Jul 22, 2022	SELL	$37.35 - $48.3 $48,218 - $62,355	-1,291 Reduced 4.08%	30,330 $1.34 Million
Q1 2022 Apr 22, 2022	BUY	$31.97 - $41.06 $3,356 - $4,311	105 Added 0.33%	31,621 $1.26 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $23,324 - $29,869	-733 Reduced 2.27%	31,516 $1.27 Million
Q3 2021 Nov 05, 2021	BUY	$38.47 - $46.42 $23,928 - $28,873	622 Added 1.97%	32,249 $1.31 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $105,994 - $140,024	2,729 Added 9.44%	31,627 $1.44 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $216,909 - $282,460	5,490 Added 23.45%	28,898 $1.21 Million
Q4 2020 Nov 19, 2021	SELL	$25.81 - $43.62 $246,872 - $417,225	-9,565 Reduced 29.01%	23,408 $1 Million
Q4 2020 Feb 18, 2021	BUY	$25.81 - $43.62 $151,582 - $256,180	5,873 Added 21.67%	32,973 $1.41 Million
Q3 2020 Nov 13, 2020	BUY	$25.74 - $29.63 $81,081 - $93,334	3,150 Added 13.15%	27,100 $711,000
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $85,231 - $140,618	5,245 Added 28.04%	23,950 $642,000
Q1 2020 May 15, 2020	SELL	$13.9 - $21.83 $27,897 - $43,812	-2,007 Reduced 9.69%	18,705 $336,000
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $309,230 - $404,505	20,712 New	20,712 $367,000

Others Institutions Holding HALO

# of Institutions

544

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.65B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.

Account

Truist Financial Corp Halozyme Therapeutics, Inc. Transaction History